ASX Announcements

Date Title
30/10/2019 Annual Report 2019
03/09/2019 Appendix 3B
07/08/2019 Appendix 3B and Cleansing Statement
01/08/2019 Appendix 3B: New issue announcement, application for quotation of additional securities and agreement
02/05/2019 Appendix 3X - Initial Director's Interest Notice
03/09/2019 Appendix 3Y - Glen Richards
03/09/2019 Appendix 3Y - Leo Lee
02/05/2019 Appendix 3Z - Final Director's Interest Notice
31/10/2019 Appendix 4C - Quarterly
31/10/2019 Appendix 4C Query and Response
30/08/2019 Appendix 4E - Preliminary final report for the year ended 30 June 2019
30/10/2019 Appendix 4G and Corporate Governance Statement
29/04/2019 Appointment of industry leaders to Regeneus Board provide foundation for global growth rollout
01/08/2019 Capital Raise up to $5.5 million supports Progenza commercialisation strategy
11/09/2019 Change of interests of substantial holder - Graham Vesey
15/10/2019 Change of Registered Office and Principal Place of Business
30/08/2019 Clarification to announcement
10/09/2019 Date of AGM
28/02/2019 Directors Provide $2.5M Loan to Extend Funding Runway
13/08/2019 Entitlement Offer - Confirmation of despatch of Entitlement Offer Booklet
11/09/2019 Form 603 - Notice of substantial holder - Leo Lee
30/07/2019 Market Announcement: Regeneus - Trading Halt
01/02/2019 Material Terms of Contract for Chief Executive Officer
23/01/2019 New CEO Appointed to Accelerate Global Growth
22/07/2019 New Strategy To Deliver Therapies For Global Pain Market
18/10/2019 Notice of Annual General Meeting / Proxy Form
01/08/2019 Offer Booklet
23/07/2019 Positive preclinical trial results for Progenza in treating neuropathic pain
30/01/2019 Quarterly results for the period ended 31 December 2018
01/08/2019 Regeneus Entitlement Offer - Notice to Option Holders
02/08/2019 Regeneus Entitlement Offer - Notice to Shareholders
15/10/2019 Regeneus receives A$1.5 million in R&D Tax Incentives
01/08/2019 Regeneus: Cleansing Notice
22/02/2019 Response to ASX Appendix 4C Query Letter
13/08/2019 Restructuring results in 50% reduction in operating costs
01/08/2019 Rights Issue Investor Presentation
07/08/2019 Rights Issue Investor Presentation
30/08/2019 Rights Issue Shortfall